Related references
Note: Only part of the references are listed.Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.
Alberto F. Sobrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
G. Argiles et al.
ANNALS OF ONCOLOGY (2020)
Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline
Christopher Lieu et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis
Alessandro Inno et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer A Systematic Review and Meta-analysis
Devon J. Boyne et al.
JAMA NETWORK OPEN (2019)
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial
Alberto Sobrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
A. Grothey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101
Lawrence N. Shulman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 129676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
D. Sargent et al.
EUROPEAN JOURNAL OF CANCER (2011)
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Share Paper
